United States was the largest of PERRIGO Co plc’s 4 reported lines in fiscal 2025, at $2.54B — 59% of $4.30B.
| Geography | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | $2.92B | $2.65B | $2.54B | ||||||||||
| U.S | $2.87B | — | — | — | ||||||||||
| Unites States | — | — | — | — | ||||||||||
| Europe | $1.47B | $1.62B | $1.60B | $1.62B | ||||||||||
| Outside United States | — | — | — | — | ||||||||||
| All Other Countries | $107.30M | $116.30M | $119.50M | $96.70M | ||||||||||
| Ireland | $29.30M | $40.80M | $39.60M | $42.10M | ||||||||||
| Total | $4.48B | $4.70B | $4.41B | $4.30B |
In fiscal 2025, which ended December 31, 2025, the 4 regions PERRIGO Co plc reported in this breakdown added up to $4.30B. That was down 2.7% from $4.41B in fiscal 2024. United States was the largest region, at $2.54B or 59.1% of the total, followed by Europe ($1.62B, 37.6%) and All Other Countries ($96.70M, 2.3%). Together, the two largest regions made up 96.8% of this total.
Compared with fiscal 2024, Europe grew the fastest, rising 0.7% to $1.62B. All Other Countries fell the most, down 19.1% to $96.70M.
The table also keeps 3 regions that PERRIGO Co plc no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2012 to 2025, as reported in PERRIGO Co plc's annual filings.
Branded Otc was the largest of PERRIGO Co plc’s 12 reported lines in fiscal 2017, at $1.17B — 24% of $4.95B.
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|
| Chc | — | — | — | — | |
| Branded Otc | — | — | $1.35B | $1.17B | |
| Generic Prescription Drugs | — | — | $1.04B | $969.70M | |
| Rx | $864.20M | — | — | — | |
| Infant Nutritionals | $374.80M | $200.20M | $427.00M | $413.90M | |
| Cough/Cold/Allergy/Sinus | — | $234.60M | $454.60M | $483.70M | |
| Cough/Cold | $477.60M | — | — | — | |
| Analgesics | $433.20M | $173.10M | $343.50M | $349.80M | |
| Other Chci | $331.10M | $167.10M | $303.00M | $317.00M | |
| Gastrointestinal | $398.40M | $195.80M | $335.40M | $340.00M | |
| Other Chca | $305.50M | $132.20M | $334.00M | $358.60M | |
| Cough, Cold, & Allergy | — | — | $348.20M | — | |
| Lifestyle | — | — | $300.20M | — | |
| Smoking Cessation | $236.80M | $147.50M | $308.50M | $297.20M | |
| Personal Care & Derma-Therapeutics | — | — | $269.10M | — | |
| Vitamins, Minerals & Dietary Supplements | — | — | $160.40M | $45.40M | |
| Vitamins, Minerals, & Dietary Supplements | $176.90M | — | — | — | |
| Animal Health | $178.00M | $62.30M | $143.70M | $141.30M | |
| Natural Health & Vitamins, Minerals And Dietary Supplements | — | — | $124.50M | — | |
| Anti-Parasite | — | — | $111.00M | — | |
| Active Pharmaceutical Ingredients | $137.60M | $45.10M | $78.50M | $55.60M | |
| Total | $3.91B | $1.36B | $6.43B | $4.95B |
In fiscal 2017, which ended December 31, 2017, the 12 revenue lines PERRIGO Co plc reported in this breakdown added up to $4.95B. The revenue lines reported changed from fiscal 2016, so the total is not directly comparable with the $6.43B reported that year. Branded Otc was the largest revenue line, at $1.17B or 23.7% of the total, followed by Generic Prescription Drugs ($969.70M, 19.6%) and Cough/Cold/Allergy/Sinus ($483.70M, 9.8%). Together, the two largest revenue lines made up 43.3% of this total.
Compared with fiscal 2016, Other Chca grew the fastest, rising 7.4% to $358.60M. Branded Otc fell the most, down 13.0% to $1.17B. Because revenue lines were added or dropped between the two years, part of this reflects how PERRIGO Co plc regrouped its reporting.
Branded Otc (fiscal 2016), Generic Prescription Drugs (fiscal 2016), Cough/Cold/Allergy/Sinus (fiscal 2015) and Vitamins, Minerals & Dietary Supplements (fiscal 2016) were first reported as separate revenue lines during this period. The table also keeps 9 revenue lines that PERRIGO Co plc no longer reports, so earlier years can still be read on their original basis; use "Show 9 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2013 to 2017, as reported in PERRIGO Co plc's annual filings.
Chci was the largest of PERRIGO Co plc’s 4 reported lines in fiscal 2017, at $1.17B — 44% of $2.68B.
| Statement Business Segments | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Rx Pharmaceuticals | — | $936.00M | — | — | $969.70M | ||
| Chci | $331.10M | $704.60M | $167.10M | $1.35B | $1.17B | ||
| Consumer Healthcare International | $331.10M | — | — | — | — | ||
| Rx | $864.20M | — | — | — | — | ||
| Chc | — | — | — | — | — | ||
| Consumer Healthcare | — | — | — | — | — | ||
| Chca | $477.60M | $455.60M | $234.60M | — | $483.70M | ||
| Nutritionals | — | — | — | — | — | ||
| Active Pharmaceutical Ingredients | — | — | — | — | — | ||
| Api | — | — | — | — | — | ||
| Other | — | $107.70M | $45.10M | — | $55.60M | ||
| All Other Segments | $137.60M | — | — | — | — | ||
| Pharaceutical & Medical Diagnostic Products | — | — | — | — | — | ||
| Total | $2.14B | $2.20B | $446.80M | $1.35B | $2.68B |
In fiscal 2017, which ended December 31, 2017, the 4 segments PERRIGO Co plc reported in this breakdown added up to $2.68B. That is less than the $4.95B in its breakdown by revenue line, so these segments do not account for all of its revenue that year. Chci was the largest segment, at $1.17B or 43.8% of the total, followed by Rx Pharmaceuticals ($969.70M, 36.1%) and Chca ($483.70M, 18.0%). Together, the two largest segments made up 79.9% of this total.
Other was first reported as a separate segment in fiscal 2015. The table also keeps 9 segments that PERRIGO Co plc no longer reports, so earlier years can still be read on their original basis; use "Show 9 discontinued" beneath the table to see them. This breakdown covers 7 fiscal years between 2012 and 2017, as reported in PERRIGO Co plc's annual filings.
PERRIGO Co plc (PRGO) breaks its revenue down by region, revenue line and segment. In fiscal 2025, its largest region was United States, with $2.54B or 59.1% of the total, followed by Europe at $1.62B (37.6%).
United States was PERRIGO Co plc's largest region in fiscal 2025, with $2.54B in revenue, 59.1% of the $4.30B reported across its 4 regions.
Branded Otc was PERRIGO Co plc's largest revenue line in fiscal 2017, with $1.17B in revenue, 23.7% of the $4.95B reported across its 12 revenue lines.
Chci was PERRIGO Co plc's largest segment in fiscal 2017, with $1.17B in revenue, 43.8% of the $2.68B reported across its 4 segments.
Of the PERRIGO Co plc regions reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Europe grew the fastest, rising 0.7% from $1.60B to $1.62B.
Every figure is taken from PERRIGO Co plc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by region covers fiscal 2012 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.